Back to search results

Evaluating LINFU™ for Early Pancreatic Cancer Detection

This study is looking at a new method called LINFU™ to find pancreatic cancer early, even before symptoms appear. LINFU™ uses a special ultrasound technique with two injected substances, Lumason and secretin, to collect pancreatic cells. These cells are then analyzed to detect pancreatic ductal adenocarcinoma (a type of pancreatic cancer) and its early, non-cancerous stages. You might be able to join if you are between 18 and 90 years old and have a higher risk of pancreatic cancer due to factors like smoking, diabetes, or family history. The study will track the number of cancers found using LINFU™ over five years. The current status of this study is unclear.

Study design
This is an observational study aiming to enroll 500 participants. It is not specified if it is randomized or blinded.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your health will be followed for a period of 5 years after the LINFU™ procedure.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04793633

Evaluating LINFU™: A Noninvasive Method for Collecting Pancreatic Cells for the Early Detection of Pancreatic Cancer

Enrolling by Invitation
Not specifiedAges 18–90Observational
Adenocyte, LLC
~500 participants
Updated 2024-03-12 on ClinicalTrials.gov
What's tested:LINFU™ Technique

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The number of pancreatic ductal adenocarcinomas and their noninvasive precursor
Measured over 5 years

Conditions

Pancreatic Ductal Adenocarcinoma

Explore related trials

Pancreatic Ductal AdenocarcinomaPancreatic Intraepithelial Neoplasia

Where it's being run

1 sites across 1 states
Florida1

Study leadership

  • Kenneth B Meredith, MD · PRINCIPAL_INVESTIGATOR · Sarasota Memorial Hospital

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

What this trial measures

  • The number of pancreatic ductal adenocarcinomas and their noninvasive precursor5 years

    The total number of asymptomatic pancreatic ductal adenocarcinomas and their noninvasive precursor lesions identified with LINFU® by analysis of pancreatic fluid will be compared to the number of these lesions identified with current screening tests, including EUS- FNA, MRI/MRCP, ERCP, CT and CEUS.